Aligned Genetics, Inc.
KKRX:2381202,565.00
KRW
+25.00
(+0.98%)
ISIN
KR7238120000
Return %
Stock
S&P 500
1Y
-21.80
13.14
3Y
-38.42
80.78
5Y
-45.13
67.74
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Yun-Chul Jung
- Full Time Employees
- 66
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- Anyang-si South Korea
- IPO Date
- Nov 3, 2016
- Website
- alignedgenetics.co.kr
- Similar Companies
- Business
- Aligned Genetics, Inc. is a South Korea-based biotechnology and life science instrumentation company specializing in the development, manufacturing, and commercialization of automated cell analysis systems, high-content digital bio-imaging instruments, tissue clearing solutions, and molecular diagnostics platforms. Founded in 2008 and headquartered in Anyang-si, Gyeonggi-do, South Korea, the company serves academic institutions, pharmaceutical corporations, contract development and manufacturing organizations (CDMOs), biotechnology enterprises, and clinical research laboratories worldwide. The company's core product and service portfolio encompasses four main categories: automated cell counting systems, digital bio-imaging platforms, tissue clearing systems, and specialized reagents and consumables. Its automated cell counting line includes the LUNA series, featuring the LUNA-II automated brightfield cell counter for routine cell counting; the LUNA-FL dual fluorescence cell counter for sensitive cell viability assessments; the LUNA-STEM automated fluorescence counter optimized for stem cell and stromal vascular fraction analysis; the LUNA-FX7 automated cell counter designed for bioprocessing, cell therapy manufacturing, and biopharmaceutical quality control with 21 CFR Part 11 compliance; and the QUANTOM Tx microbial cell counter for rapid single-cell bacterial quantification. Its digital bio-imaging offerings comprise the CELENA S digital imaging system for multi-channel fluorescence, brightfield, and phase contrast microscopy, alongside the CELENA X high-content imaging system configured for automated image-based screening and quantitative phenotypic assays. The tissue clearing segment features the X-CLARITY tissue clearing system, an electrophoretic tissue clearing instrument based on the CLARITY method for whole-organ and three-dimensional tissue visualization, complemented by proprietary hydrogel matrices, electrophoretic reagents, and optical clearing mounting solutions. In addition, the company manufactures and distributes precision consumables, including PhotonSlide disposable slides, LUNA counting chambers, fluorescent viability stains, calibration standards, and image analysis software suites. In recent developments, the company executed a corporate rebranding from Logos Biosystems, Inc. to Aligned Genetics, Inc. to reflect its strategic transition from life science imaging hardware into genomics, spatial biology, and advanced molecular diagnostic technologies. To support this strategic pivot, Aligned Genetics has expanded its bioprocessing analytics portfolio, accelerating commercial adoption of the LUNA-FX7 across global cell and gene therapy (CGT) manufacturing workflows. The company maintains international operations through regional sales and support subsidiaries, including Aligned Genetics US in Virginia, United States, and Logos Biosystems Europe in Lille, France, while strengthening distribution alliances across North America, Europe, and Asia-Pacific. Furthermore, Aligned Genetics continues to advance internal research and commercialization programs focused on microfluidic lab-on-a-chip genetic diagnostic platforms and next-generation automated spatial biology imaging systems.